Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.46 |
| ▸ | MAOA | P21397 | 16/20 | 0.46 |
| ▸ | MAOB | P27338 | 16/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307974 | 0.92 | KDM1A (0.48) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL5435422 | 0.88 | MAPK1 (0.50) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL28206522 | 0.86 | KDM1A (0.43) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL4133969 | 0.84 | KDM1A (0.44) | KDM1AMAOAMAOB | |
| SCHEMBL4134830 | 0.84 | KDM1A (0.41) | KDM1AMAOAMAOB | |
| SCHEMBL4134868 | 0.84 | KDM1A (0.48) | KDM1A | |
| SCHEMBL4150540 | 0.82 | KDM1A (0.40) | KDM1AMAOAMAOB | |
| SCHEMBL4134001 | 0.82 | KDM1A (0.47) | KDM1A | |
| SCHEMBL8905787 | 0.82 | F2 (0.40) | — | |
| SCHEMBL2594172 | 0.78 | KDM1A (0.44) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | KDM1A 3042/4885MAOA 2039/4885MAOB 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.